Early ReportPersistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues
Introduction
The antiretroviral nucleoside analogue zidovudine can lower the rate of mother-to-child transmission of HIV-1 infection.1 Official recommendations to use this preventive treatment during the second half of pregnancy, labour, and for the first 6 weeks of life in neonates2 have led to a substantial decrease in the number of infected children in more-developed countries.3, 4 Simplified regimens adapted to the medical and economic conditions in Africa and South Asia have also been effective.5
Tolerance of this treatment has been a concern.6, 7, 8 The data from the first protocol9 and later observational studies were reassuring. The most common secondary effect was, as expected, transient and rarely severe macrocytic anaemia. Whether late side-effects appear after the period during which children are not infected by HIV-1 is not clear. This question prompted long-term follow-up studies10 and the establishment of national registers for antiretroviral prescriptions during pregnancy. The development of multidrug antiretroviral therapies reinforces the need for such studies because many HIV-1-infected women have received zidovudine in combination with other nucleoside analogues, especially lamivudine, since 1995. We report mitochondrial dysfunction in unrelated children, free of HIV-1 infection, exposed in utero and postnatally to one or two nucleoside analogues.
Section snippets
Patients
The French National Epidemiological Network for studying mother-to-child transmission of HIV-1 (Enquête Périnatale Francaise) is an epidemiological survey that was started in 1986 and involves more than 90 obstetrics and paediatrics centres throughout France. All participating centres adhere to a common monitoring schedule and include all seropositive women who agree to participate. By Jan 15, 1999, 3779 mother-child pairs were included, of which 1754 were exposed to zidovudine or other drugs
Patients
Eight children with mitochondrial dysfunction were found. The first two patients were identified by the analysis for serious adverse events of ANRS075. The other six patients were identified during continuing retrospective screening for mitochondrial symptoms among patients enrolled in the national epidemiological survey since 1986 and in the therapeutic trial (table 1).
At age 4·5 months, the first patient presented with visual impairment. Cerebral nuclear magnetic resonance imaging showed
Discussion
The clinical and biological symptoms of these eight children, and especially the persistently increased blood lactate concentrations in five of them, are compatible with mitochondrial respiratory-chain dysfunction. This diagnosis is supported by specific tissue and cell mitochondrial analyses. Caution is required in interpretation of the enzymology results because of the variations in control populations. We took only values substantially different from normal to be informative. We used ratios
References (28)
- et al.
Acceptability and impact of zidovudine prevention on mother to child HIV-1 transmission in France
J Pediatr
(1997) Short courses of zidovudine halves HIV-1 perinatal transmission
Lancet
(1998)- et al.
Biochemical molecular investigations in respiratory chain deficiency
Clin Chim Acta
(1994) - et al.
An improved representation of enzyme activities for assessment of the mitochondrial respiratory chain
Lancet
(1991) Mitochondrial gene mutations
Eur J Paediatr Neurol
(1998)- et al.
Fate and expression of the deleted mitochondrial DNA differ between human heteroplasmic skin fibroblasts and Epstein-Barr virus-transformed lymphocyte cultures
J Biol Chem
(1993) Mitochondrial mutations and hearing loss: paradigm for mitochondrial genetics
Am J Hum Genet
(1998)- et al.
Reduction of maternal infant transmission of human immunodeficiency virus type 1 with zidovudine treatment
N Engl J Med
(1994) Recommendations of the US Public Health service task force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus
MMWR Morb Mortal Wkty Rep
(1994)Success in implementing Public Health Service Guidelines to reduce perinatal transmission of HIV: Louisiana, Michigan, New Jersey and South Carolina 1993, 1995 and 1996
MMWR Morb Mortal Wkly Rep
(1998)
Zidovudine for the prevention of vertical HIV transmission: a decision analytic approach
J Acquir Immune Defic Syndr Hum Retrovirol
Zidovudine for mother, fetus and child: hope or poison?
Lancet
A risk-benefit assessment of zidovudine in the prevention of perinatal HIV transmission
Drug Saf
Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study
AIDS
Cited by (599)
Infections in pregnancy: Recent therapeutic advances
2022, Bulletin de l'Academie Nationale de MedecineHIV in pregnancy: Mother-to-child transmission, pharmacotherapy, and toxicity
2021, Biochimica et Biophysica Acta - Molecular Basis of DiseaseBrain microstructural changes support cognitive deficits in HIV uninfected children born to HIV infected mothers
2020, Brain, Behavior, and Immunity - HealthMaintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study
2023, Journal of Antimicrobial Chemotherapy